Justin M. Holub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Justin M. Holub has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Danushka Arachchige
Department of Chemistry and Biochemistry Ohio University Athens Ohio USA
4 shared publications- John Joseph Kopchick
Heritage College of Osteopathic Medicine, Ohio University, United States
2 shared publications Khairun Nahar
Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701
2 shared publicationsM. Margaret Harris
Department of Chemistry and Biochemistry, Ohio University, Athens, OH, 45701, USA
2 shared publicationsNajah Alqaeisoom
Ohio University
2 shared publicationsRanju Pokhrel
Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio, USA
2 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (4)
A helical peptide antagonist of the human growth hormone receptor
The binding of human growth hormone (hGH) to the human growth hormone receptor (hGHR) is a key endocrinological process that controls critical aspects of cell growth, proliferation and differentiation. Mechanistically, this sequential, asymmetric binding event involves the interaction between a single hGH molecule and distinct sites (site 1 and site 2) on the extracellular domain of a preformed hGHR homodimer. Our group recently identified S1H, a rationally-designed peptide sequence mimetic of the hGH site 1-binding helix (residues 36-51) that disrupts the hGH-hGHR interaction and inhibits hGH-mediated phosphorylation of signal transducer and activator of transcription 5 (STAT5) in hGHR-positive cell lines. Structure-activity relationship studies revealed a positive correlation between helical propensity and inhibitory potency of the S1H peptide, prompting the design of structurally “stabilized” S1H variants (SS1H) with improved biological activity. In this study, we employed a chemical strategy, termed hydrocarbon stapling, to generate a series of SS1H peptides that proved to be more helical, proteolytically stable and biologically active compared to linear (unstructured) S1H. Notably, one SS1H derivative (SS1HB) inhibited hGH-induced STAT5 phosphorylation in hGHR-positive human bladder cancer cells more effectively than pegvisomant, the only hGHR antagonist currently approved by the FDA. Collectively, our results demonstrate that hydrocarbon stapling improves the antagonistic effects of S1H peptides and elevates their potential as chemical probes to study the molecular mechanisms of hGH signaling. It is also anticipated that SS1H peptides will serve as potent lead compounds for developing next-generation therapeutics designed to treat endocrine disorders that manifest along the hGH-hGHR signaling axis.
- 26 February 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (4)
Open AccessA helical peptide antagonist of the human growth hormone receptor
The binding of human growth hormone (hGH) to the human growth hormone receptor (hGHR) is a key endocrinological process that controls critical aspects of cell growth, proliferation and differentiation. Mechanistically, this sequential, asymmetric binding event involves the interaction between a single hGH molecule and distinct sites (site 1 and site 2) on the extracellular domain of a preformed hGHR homodimer. Our group recently identified S1H, a rationally-designed peptide sequence mimetic of the hGH site 1-binding helix (residues 36-51) that disrupts the hGH-hGHR interaction and inhibits hGH-mediated phosphorylation of signal transducer and activator of transcription 5 (STAT5) in hGHR-positive cell lines. Structure-activity relationship studies revealed a positive correlation between helical propensity and inhibitory potency of the S1H peptide, prompting the design of structurally “stabilized” S1H variants (SS1H) with improved biological activity. In this study, we employed a chemical strategy, termed hydrocarbon stapling, to generate a series of SS1H peptides that proved to be more helical, proteolytically stable and biologically active compared to linear (unstructured) S1H. Notably, one SS1H derivative (SS1HB) inhibited hGH-induced STAT5 phosphorylation in hGHR-positive human bladder cancer cells more effectively than pegvisomant, the only hGHR antagonist currently approved by the FDA. Collectively, our results demonstrate that hydrocarbon stapling improves the antagonistic effects of S1H peptides and elevates their potential as chemical probes to study the molecular mechanisms of hGH signaling. It is also anticipated that SS1H peptides will serve as potent lead compounds for developing next-generation therapeutics designed to treat endocrine disorders that manifest along the hGH-hGHR signaling axis.
- Open Access
- 4 February 2025
- Published by Wiley in Journal of Molecular Recognition
- Vol. 38 (2) , e70001
Inhibitory Potential and Binding Thermodynamics of Scyllatoxin‐Based BH3 Domain Mimetics Targeting Repressor BCL2 Proteins
The B‐cell lymphoma 2 (BCL2) proteins are a class of apoptosis regulators that control the release of apoptogenic factors from mitochondria. Under normal physiological conditions, apoptosis is inhibited through the actions of anti‐apoptotic (repressor) BCL2 proteins that bind semi‐indiscriminately to the helical BH3 domains of pro‐apoptotic (effector) BCL2 proteins. In this work, we developed a series of BH3 domain mimetics by grafting residues from the effector BCL2 protein Bax onto the α‐helix of scyllatoxin (ScTx). These so‐called “ScTx‐Bax” constructs were then used to gain insight into the physicochemical nature of repressor/effector BCL2 interactions. Specifically, we utilized competitive binding and isothermal titration calorimetry (ITC) to investigate the inhibitory potential and binding thermodynamics of ScTx‐Bax structural variants that target the repressor protein Bcl‐2 (proper) in vitro. Our data show that ScTx‐Bax mimetics compete with isolated Bax BH3 domain peptides for Bcl‐2 with IC50 values in the mid‐nanomolar range and that greater flexibility within the ScTx‐Bax BH3 domain correlates with more effective inhibition. Furthermore, ITC experiments revealed that unstructured ScTx‐Bax variants target Bcl‐2 with greater entropic, but lower enthalpic, efficiencies than structured ScTx‐Bax peptides. These results suggest that entropic contributions to binding Bcl‐2 are more favorable for flexible BH3 domains; however, this enhancement is counterbalanced by a moderate enthalpic penalty. Overall, this study improves understanding of how structural properties of effector BH3 domains influence the promiscuous binding patterns of BCL2 proteins and expands the utility of ScTx‐based BH3 domain mimetics as molecular tools to study discrete recognition elements that facilitate repressor/effector BCL2 interactions.
- 4 February 2025
- Published by Wiley in Journal of Molecular Recognition
- Vol. 38 (2) , e70001
Open AccessInhibitory Potential and Binding Thermodynamics of Scyllatoxin‐Based BH3 Domain Mimetics Targeting Repressor BCL2 Proteins
The B‐cell lymphoma 2 (BCL2) proteins are a class of apoptosis regulators that control the release of apoptogenic factors from mitochondria. Under normal physiological conditions, apoptosis is inhibited through the actions of anti‐apoptotic (repressor) BCL2 proteins that bind semi‐indiscriminately to the helical BH3 domains of pro‐apoptotic (effector) BCL2 proteins. In this work, we developed a series of BH3 domain mimetics by grafting residues from the effector BCL2 protein Bax onto the α‐helix of scyllatoxin (ScTx). These so‐called “ScTx‐Bax” constructs were then used to gain insight into the physicochemical nature of repressor/effector BCL2 interactions. Specifically, we utilized competitive binding and isothermal titration calorimetry (ITC) to investigate the inhibitory potential and binding thermodynamics of ScTx‐Bax structural variants that target the repressor protein Bcl‐2 (proper) in vitro. Our data show that ScTx‐Bax mimetics compete with isolated Bax BH3 domain peptides for Bcl‐2 with IC50 values in the mid‐nanomolar range and that greater flexibility within the ScTx‐Bax BH3 domain correlates with more effective inhibition. Furthermore, ITC experiments revealed that unstructured ScTx‐Bax variants target Bcl‐2 with greater entropic, but lower enthalpic, efficiencies than structured ScTx‐Bax peptides. These results suggest that entropic contributions to binding Bcl‐2 are more favorable for flexible BH3 domains; however, this enhancement is counterbalanced by a moderate enthalpic penalty. Overall, this study improves understanding of how structural properties of effector BH3 domains influence the promiscuous binding patterns of BCL2 proteins and expands the utility of ScTx‐based BH3 domain mimetics as molecular tools to study discrete recognition elements that facilitate repressor/effector BCL2 interactions.
- Open Access
- 27 January 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108231
Surveying helix 12 dynamics within constitutively active estrogen receptors using bipartite tetracysteine display
- 27 January 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108231
Open AccessSurveying helix 12 dynamics within constitutively active estrogen receptors using bipartite tetracysteine display
- 22 June 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (26) , 9111-9118
Versatile Gold-Coupled Te-Carbon Dots for Quantitative Monitoring and Efficient Scavenging of Superoxide Anions
The superoxide anion (O2•–) is a reactive oxygen species (ROS) that functions as an important regulator of signal transduction in living systems. However, excess O2•– can cause metabolic imbalances and oxidative damage inside cells. Quantitative detection and efficient scavenging of O2•– are therefore critical for maintaining intracellular redox balance and homeostasis. In this work, a nanomaterial (Au-TeCD) composed of BSA-modified gold nanoparticles (AuNPs) complexed with tellurium-containing carbon dots (TeCDs) was constructed. The introduction of Au-TeCDs to solutions containing superoxide resulted in enhanced elimination of the anion, indicating that Au-TeCDs are able to scavenge O2•– from the surrounding environment. Notably, the respective TeCD and AuNP components of the Au-TeCDs were found to emit fluorescence at 425 and 640 nm upon exposure to superoxide anions. This unique spectroscopic property of Au-TeCDs allowed levels of O2•– in solution to be quantified using dual-fluorescence detection. The Au-TeCDs developed herein also exhibited low-cytotoxicity, versatile capabilities for in situ fluorescence imaging, and effective scavenging of O2•– in living cells. Taken together, these results suggest that Au-TeCDs act as effective tools for monitoring superoxide concentrations in complex mixtures and may be developed as possible therapeutics designed to scavenge excess ROS from diseased cells.
- 22 June 2021
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 93 (26) , 9111-9118
Versatile Gold-Coupled Te-Carbon Dots for Quantitative Monitoring and Efficient Scavenging of Superoxide Anions
The superoxide anion (O2•–) is a reactive oxygen species (ROS) that functions as an important regulator of signal transduction in living systems. However, excess O2•– can cause metabolic imbalances and oxidative damage inside cells. Quantitative detection and efficient scavenging of O2•– are therefore critical for maintaining intracellular redox balance and homeostasis. In this work, a nanomaterial (Au-TeCD) composed of BSA-modified gold nanoparticles (AuNPs) complexed with tellurium-containing carbon dots (TeCDs) was constructed. The introduction of Au-TeCDs to solutions containing superoxide resulted in enhanced elimination of the anion, indicating that Au-TeCDs are able to scavenge O2•– from the surrounding environment. Notably, the respective TeCD and AuNP components of the Au-TeCDs were found to emit fluorescence at 425 and 640 nm upon exposure to superoxide anions. This unique spectroscopic property of Au-TeCDs allowed levels of O2•– in solution to be quantified using dual-fluorescence detection. The Au-TeCDs developed herein also exhibited low-cytotoxicity, versatile capabilities for in situ fluorescence imaging, and effective scavenging of O2•– in living cells. Taken together, these results suggest that Au-TeCDs act as effective tools for monitoring superoxide concentrations in complex mixtures and may be developed as possible therapeutics designed to scavenge excess ROS from diseased cells.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100588
A novel peptide antagonist of the human growth hormone receptor
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100588
Open AccessA novel peptide antagonist of the human growth hormone receptor
- 29 July 2020
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 18 (31) , 6063-6071
Monitoring ligand-mediated helix 12 transitions within the human estrogen receptor α using bipartite tetracysteine display
Estrogen receptor α ligand-binding domains (ERα-LBD) expressing tetracysteine motifs bind FlAsH-EDT2 upon transition of helix 12 (H12) to a folded state. Changes in fluorescence intensity allowed surveillance of ligand-mediated H12 transitions and facilitated the determination of FlAsH association rates (kon) and apparent equilibrium dissociation constants (Kapp) to ERα-LBDs in the presence of estrogenic ligands.
- 29 July 2020
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 18 (31) , 6063-6071
Monitoring ligand-mediated helix 12 transitions within the human estrogen receptor α using bipartite tetracysteine display
Estrogen receptor α ligand-binding domains (ERα-LBD) expressing tetracysteine motifs bind FlAsH-EDT2 upon transition of helix 12 (H12) to a folded state. Changes in fluorescence intensity allowed surveillance of ligand-mediated H12 transitions and facilitated the determination of FlAsH association rates (kon) and apparent equilibrium dissociation constants (Kapp) to ERα-LBDs in the presence of estrogenic ligands.
- 1 October 2018
- Published by Springer Nature in The Protein Journal
- Vol. 37 (5) , 428-443
Synthesis and Biological Activity of Scyllatoxin-Based BH3 Domain Mimetics Containing Two Disulfide Linkages
The B cell lymphoma 2 (BCL2) proteins are a family of evolutionarily related proteins that act as positive or negative regulators of the intrinsic apoptosis pathway. Overexpression of anti-apoptotic BCL2 proteins in cells is associated with apoptotic resistance, which can result in cancerous phenotypes and pathogenic cell survival. Consequently, anti-apoptotic BCL2 proteins have attracted considerable interest as therapeutic targets. We recently reported the development of a novel class of synthetic protein based on scyllatoxin (ScTx) designed to mimic the helical BH3 interaction domain of the pro-apoptotic BCL2 protein Bax. These studies showed that the number and position of native disulfide linkages contained within the ScTx-Bax structure significantly influences the ability for these constructs to target anti-apoptotic BCL2 proteins in vitro. The goal of the present study is to investigate the contribution of two disulfide linkages in the folding and biologicalactivity of ScTx-Bax proteins. Here, we report the full chemical synthesis of three ScTx-Bax sequence variants, each presenting two native disulfide linkages at different positions within the folded structure. It was observed that two disulfide linkages were sufficient to fold ScTx-Bax proteins into native-like architectures reminiscent of wild-type ScTx. Furthermore, we show that select (bis)disulfide ScTx-Bax variants can target Bcl-2 (proper) in vitro and that the position of the disulfide bonds significantly influences binding affinity. Despite exhibiting only modest binding to Bcl-2, the successful synthesis of ScTx-Bax proteins containing two disulfide linkages represents a viable route to ScTx-based BH3 domain mimetics that preserve native-like conformations. Finally, structural models of ScTx-Bax proteins in complex with Bcl-2 indicate that these helical mimetics bind in similar configurations as wild-type Bax BH3 domains. Taken together, these results suggest that ScTx-Bax proteins may serve as potent lead compounds that expand the repertoire of druggable protein-protein interactions.
- 1 October 2018
- Published by Springer Nature in The Protein Journal
- Vol. 37 (5) , 428-443
Synthesis and Biological Activity of Scyllatoxin-Based BH3 Domain Mimetics Containing Two Disulfide Linkages
The B cell lymphoma 2 (BCL2) proteins are a family of evolutionarily related proteins that act as positive or negative regulators of the intrinsic apoptosis pathway. Overexpression of anti-apoptotic BCL2 proteins in cells is associated with apoptotic resistance, which can result in cancerous phenotypes and pathogenic cell survival. Consequently, anti-apoptotic BCL2 proteins have attracted considerable interest as therapeutic targets. We recently reported the development of a novel class of synthetic protein based on scyllatoxin (ScTx) designed to mimic the helical BH3 interaction domain of the pro-apoptotic BCL2 protein Bax. These studies showed that the number and position of native disulfide linkages contained within the ScTx-Bax structure significantly influences the ability for these constructs to target anti-apoptotic BCL2 proteins in vitro. The goal of the present study is to investigate the contribution of two disulfide linkages in the folding and biologicalactivity of ScTx-Bax proteins. Here, we report the full chemical synthesis of three ScTx-Bax sequence variants, each presenting two native disulfide linkages at different positions within the folded structure. It was observed that two disulfide linkages were sufficient to fold ScTx-Bax proteins into native-like architectures reminiscent of wild-type ScTx. Furthermore, we show that select (bis)disulfide ScTx-Bax variants can target Bcl-2 (proper) in vitro and that the position of the disulfide bonds significantly influences binding affinity. Despite exhibiting only modest binding to Bcl-2, the successful synthesis of ScTx-Bax proteins containing two disulfide linkages represents a viable route to ScTx-based BH3 domain mimetics that preserve native-like conformations. Finally, structural models of ScTx-Bax proteins in complex with Bcl-2 indicate that these helical mimetics bind in similar configurations as wild-type Bax BH3 domains. Taken together, these results suggest that ScTx-Bax proteins may serve as potent lead compounds that expand the repertoire of druggable protein-protein interactions.
- 8 March 2018
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 25 (2) , 447-463
Inhibiting Phosphorylation of Tau (τ) Proteins at Ser262 Using Peptide-Based R1 Domain Mimetics
- 8 March 2018
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 25 (2) , 447-463
Inhibiting Phosphorylation of Tau (τ) Proteins at Ser262 Using Peptide-Based R1 Domain Mimetics
- 10 August 2017
- Published by Wiley in Drug Development Research
- Vol. 78 (6) , 268-282
Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents
Preclinical Research Miniature proteins are a class of oligopeptide characterized by their short sequence lengths and ability to adopt well‐folded, three‐dimensional structures. Because of their biomimetic nature and synthetic tractability, miniature proteins have been used to study a range of biochemical processes including fast protein folding, signal transduction, catalysis and molecular transport. Recently, miniature proteins have been gaining traction as potential therapeutic agents because their small size and ability to fold into defined tertiary structures facilitates their development as protein‐based drugs. This research overview discusses emerging developments involving the use of miniature proteins as scaffolds to design novel therapeutics for the treatment and study of human disease. Specifically, this review will explore strategies to: (i) stabilize miniature protein tertiary structure; (ii) optimize biomolecular recognition by grafting functional epitopes onto miniature protein scaffolds; and (iii) enhance cytosolic delivery of miniature proteins through the use of cationic motifs that facilitate endosomal escape. These objectives are discussed not only to address challenges in developing effective miniature protein‐based drugs, but also to highlight the tremendous potential miniature proteins hold for combating and understanding human disease. Drug Dev Res 78 : 268–282, 2017.
- 10 August 2017
- Published by Wiley in Drug Development Research
- Vol. 78 (6) , 268-282
Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents
Preclinical Research Miniature proteins are a class of oligopeptide characterized by their short sequence lengths and ability to adopt well‐folded, three‐dimensional structures. Because of their biomimetic nature and synthetic tractability, miniature proteins have been used to study a range of biochemical processes including fast protein folding, signal transduction, catalysis and molecular transport. Recently, miniature proteins have been gaining traction as potential therapeutic agents because their small size and ability to fold into defined tertiary structures facilitates their development as protein‐based drugs. This research overview discusses emerging developments involving the use of miniature proteins as scaffolds to design novel therapeutics for the treatment and study of human disease. Specifically, this review will explore strategies to: (i) stabilize miniature protein tertiary structure; (ii) optimize biomolecular recognition by grafting functional epitopes onto miniature protein scaffolds; and (iii) enhance cytosolic delivery of miniature proteins through the use of cationic motifs that facilitate endosomal escape. These objectives are discussed not only to address challenges in developing effective miniature protein‐based drugs, but also to highlight the tremendous potential miniature proteins hold for combating and understanding human disease. Drug Dev Res 78 : 268–282, 2017.